A POSSIBILITY OF THE USE OF ENDURACIN IN PATIENTS WITH CORONARY ARTERY DISEASE FOR CORRECTION OF PROATHEROGENIC SIDE EFFECTS OF LONG-TERM BETA-ADRENOBLOCKER THERAPY

V.P. Miktun
Kursk State Medical Unuversity,
Kursk, Russia

A study was made of the effect of obsidan (160-240 mg/day) combined with enduracin (Ig/day) on the atherogenic blood lipid concentration in patients suffering from coronary artery disease. The six-month obsidan therapy resulted in a decrease of HDL cholesterol, apoAl and an increase of LDL cholesterol, apoB, and triglycerides in blood plasma. The combined use of enduracin and obsidan allowed to prevent proatherogenic effects of obsidan. The plasma content of HDL cholesterol rose; there was no lowering of apoAl or trig-lyceride increase. The concentration of LDL cholesterol diminished.

P. 18-21

« Back